Researchers at the University of South Australia have developed a disposable device that can identify aggressive breast cancers.
Patients with aggressive breast cancers have abnormal levels of protein HER2 in their blood.
Model and validation studies conducted by the researchers showed that the microfluidic device is able to capture HER2 positive cells from blood with 80% accuracy.
Study researcher Benjamin Thierry said that microfluidic devices offer a unique opportunity to efficiently isolate circulating tumour cells from patient’s blood.
“We hope that our device will provide a fast, reliable and affordable methodology to establish HER2 status for breast cancer patients presenting metastases, thereby enabling the selection of more potent therapy based on trastuzumab,” Thierry added.